Previous 10 | Next 10 |
Amarin (NASDAQ: AMRN ) is collaborating with HLS Therapeutics to study Vascepa's effects on inflammatory biomarkers in those with COVID-19. More news on: Amarin Corporation plc, Healthcare stocks news, Stocks on the move, Read more ...
DUBLIN, Ireland and BRIDGEWATER, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), today announced support for a clinical trial to investigate the effects of icosapent ethyl (IPE) (VASCEPA®) on inflammatory biomarkers and other patient outcomes in indivi...
Amarin ( AMRN ) filed its legal brief using a new lawyer - Jonathan Singer - who was lead attorney in the well-known in re cyclobenzaprine case , which is directly relevant to Amarin’s situation. Therefore, on the one hand, it's great that Amarin has been able to rope in the lawyer w...
Irish biopharmaceutical company Amarin (NASDAQ: AMRN) posted record revenue of $155 million in its first-quarter earnings reported April 30, marking an 112% year-over-year increase for a net loss of $20.6 million, or $0.06 per share. The company's sole product, Vascepa, is a drug derive...
Amarin ( AMRN ) had its task cut out for it couple years back. I was making a list, here’s how it looks: Take the FDA to court on First Amendment rights, and win - CHECK Successfully complete the REDUCE-IT trial showing Vascepa’s unique ability to reduce cardiovascular ri...
First and total coronary revascularization event reductions of 34% and 36%, respectively, shown with VASCEPA in prespecified tertiary endpoint analyses Results of prespecified tertiary endpoint analyses consistent across different types of coronary revascularization procedures, includ...
Initial public offerings, or IPOs, usually garner lots of attention. And why not? Like sports teams jockeying for top prospects on draft day, investors line up to own a piece of the company as it commences trading. The company, its employees, and existing investors clamor to see whether the stoc...
Amarin Corporation plc (AMRN) Q1 2020 Update Earnings Conference Call April 30, 2020 7:30 AM ET Company Participants Elisabeth Schwartz - Senior Director, Investor Relations John Thero - President & CEO Mike Kalb - CFO Conference Call Participants Jessica Fye - JPMo...
The following slide deck was published by Amarin Corporation plc in conjunction with their 2020 Q1 earnings Read more ...
Amarin ( AMRN ) Q1 results : More news on: Amarin Corporation plc, Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...